LOS ALTOS, Calif. — February 4, 2026 — Leads & Copy — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) has announced that CEO Shalabh Gupta, M.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 1:30 p.m. ET.
Unicycive Therapeutics, a clinical-stage biotechnology company, focuses on developing therapies for patients with kidney disease.
The live and archived webcast will be available on the Unicycive website under the Investors section: Events and Presentations.
Those interested in scheduling a 1×1 meeting with management can contact their Guggenheim conference representative.
Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The company’s second investigational treatment, UNI-494, is intended for treating conditions related to acute kidney injury. UNI-494 has been granted orphan drug designation by the FDA for preventing Delayed Graft Function in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers.
Source: Unicycive Therapeutics, Inc.
